Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-04-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于会计师事务所2024年度履职情况评估及审计委员会履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the company's board and audit committee evaluating the performance of the auditing firm for the 2024 fiscal year. It discusses the audit firm's qualifications, the audit process, and the audit committee's supervision activities. It includes details about the audit engagement, communication with auditors, and the issuance of an unqualified audit opinion. The document does not contain the full annual report or financial statements but is a standalone report on audit performance and oversight. This matches the definition of an Audit Report / Information (AR). The document length is 2055 characters, which is relatively short but contains substantive content about audit evaluation rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-24 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "赛隆药业集团股份有限公司2024 年年度报告全文" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2024 Annual Report Full Text." It contains detailed sections including company overview, financial data for the year 2024, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes signed financial statements, audit reports, and detailed financial and operational data for the full fiscal year 2024. These characteristics align with the definition of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2025-04-24 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a statement from the company's board regarding the independence of its independent directors, referencing regulatory requirements and confirming compliance. It does not contain financial data, audit results, or detailed management discussion. It is a governance-related disclosure about board members' independence, which fits best under Governance Information (CGR). The document length is short and focused on governance compliance rather than financial or operational reporting.
2025-04-24 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2024 by Sailong Pharmaceutical Group Co., Ltd. It references an audit report issued by an accounting firm with an unqualified opinion on the 2024 financial statements. The document includes a summary table of related party transactions and states that the summary should be read together with the audited financial statements. The document is a standalone audit-related explanation focusing on specific regulatory requirements about fund usage and related party transactions, not a full annual report or financial statement. It is not a report publication announcement or a certification letter but a detailed audit-related disclosure. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive audit-related content, not just an announcement or certification. FY 2024
2025-04-24 Chinese
2024独立董事述职报告（陈小辛）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" for a listed company. It details the independent director's activities, attendance at board and shareholder meetings, participation in committees, communication with auditors, and overall evaluation of their duties during the year 2024. It does not contain financial statements or audit opinions but focuses on governance and director duties. This type of document is a report on board/management information, specifically about the independent director's role and activities. It is not an annual report, audit report, or regulatory filing. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3213 characters, which is consistent with a detailed report but not a full financial report.
2025-04-24 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to "2024 Supervisory Board Work Report". It details the activities, meetings, and oversight functions of the supervisory board for the year 2024. It includes summaries of meetings, opinions on company operations, financial oversight, internal controls, related party transactions, and plans for 2025. The document is a formal report from the supervisory board rather than an announcement or a brief notice. It does not contain full financial statements or detailed financial data typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification or a regulatory filing. The content aligns with a Management Report (MDA) as it provides management's detailed explanation of company oversight, business trends, and outlook. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the best classification is Management Reports (MDA).
2025-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.